Eight years of experience with vismodegib for advanced and multiple basal cell carcinoma patients in the Netherlands: a retrospective cohort study

BACKGROUND: Vismodegib has been used for the treatment of locally advanced basal cell carcinoma (laBCC) and metastatic BCC (mBCC) since 2011. Most efficacy and safety data are provided by clinical trials. This study evaluates the effectiveness of vismodegib for the treatment of laBCC, mBCC and basal...

Descripción completa

Detalles Bibliográficos
Autores principales: Verkouteren, Babette J. A., Wakkee, Marlies, Reyners, An K. L., Nelemans, Patty, Aarts, Maureen J. B., Rácz, Emőke, Terra, Jorrit B., Devriese, Lot A., Alers, Robert-Jan, Kapiteijn, Ellen, van Doorn, Remco, Bekkenk, Marcel W., Reinders, Marie G.H.C., Mosterd, Klara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007568/
https://www.ncbi.nlm.nih.gov/pubmed/33462360
http://dx.doi.org/10.1038/s41416-020-01220-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007568/
https://www.ncbi.nlm.nih.gov/pubmed/33462360
http://dx.doi.org/10.1038/s41416-020-01220-w

Ejemplares similares